Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
Go back to Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas| Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) | Delayed: 15.63 -0.13 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.76 | 52 Week High | $26.24 | |||
| Open | $15.60 | 52 Week Low | $18.86 | |||
| Day High | $15.64 | P/E | N/A | |||
| Day Low | $15.56 | EPS | $0.00 | |||
| Volume | 474,939 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 119.60 +4.12 (3.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $119.80 | P/E | 81.36 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 11,893,949 | |||||
